This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Novartis Pharma GmbH.
Reference
Seddik AH, et al. The Societal Economic Impact of Secukinumab in First-Line Treatment of Moderate to Severe Plaque Psoriasis in Germany: An Open-Cohort Simulation. PharmacoEconomics-Open : 19 Oct 2021. Available from: URL: https://doi.org/10.1007/s41669-021-00305-3
Rights and permissions
About this article
Cite this article
Societal economic impact of use secukinumab for treatment of psoriasis in Germany "potentially significant". PharmacoEcon Outcomes News 890, 26 (2021). https://doi.org/10.1007/s40274-021-08149-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08149-y